

Ensure JCA success

IQVIA EU HTA Solutions: Your partner at global, regional and local level

The implementation of the new European Health Technology Assessment (EU HTA) regulation represents a fundamental turning point for health technology developers (HTDs), HTA bodies, payers, and patients.


Since 12th January 2025, the HTA clinical assessment of new cancer drugs and Advanced Therapy Medicinal Products (ATMPs) are conducted centrally. These Joint Clinical Assessments (JCAs) aim to streamline HTA efforts across EU Member States and ultimately accelerate patient access to innovative medicines. By 2030, the new HTA process will be rolled out for all drugs, vaccines, in-vitro diagnostics and high-risk medical devices.

What this means for you

Although this new era holds significant promise for all stakeholders, HTDs need to adjust their current market access strategies and launch preparations to align with the evolving environment. This will ensure they maximize the benefits of the new HTA process.

Although all guidance documents on the EU HTA process and assessment methodology for medicinal products have been published, uncertainty remains around their implementation. HTDs need to accommodate these uncertainties in their evidence and tactical planning, not just for assets eligible for the EU JCA in 2025, but also for their pipeline products, to ensure future EU HTA success.

How the new EU HTA process impacts the way health technology developers prepare for market access



Although this new era holds significant promise for all stakeholders, HTDs need to adjust their current market access strategies and launch preparations to align with the evolving environment.

How IQVIA can help you


With hands-on experience in the development of European HTA dossiers (500+ in the last five years, >100 in Germany alone), IQVIA can be the right partner for you to successfully work through the uncertainties of the new process.

Our dedicated EU HTA Solutions team can support you with robust preparation for EU HTA through end-to-end services, ranging from global strategy development and evidence generation, including JCA statistical analysis plan development and analysis, to dossier development and local execution. As recognized thought leaders in EU HTA, we understand that you need a holistic and cross-functional approach to ensure that you and your organization are ready in time — at a global, regional and local level.

Our offering connects IQVIA's broad European network of >1,800 local "on-the-ground" market experts, our proprietary data sources and tools, and our unique combination of expertise ranging from HEOR, evidence synthesis and market access to clinical and technical expertise and organizational redesign, to create an effective solution tailored to your needs. Our centralized management ensures efficient and integrated delivery while building a close partnership on your EU HTA journey.

IQVIA's offering connects in-depth local HTA expertise, strategic thinking and technical expertise.

IQVIA's EU HTA Solutions team provides end-to-end support



Abbreviations: EU: European Union; HTA: Health Technology Assessment; HTAR: HTA Regulation; HTD: Health Technology Developer; JCA: Joint Clinical Assessment; JSC: Joint Scientific Consultation; KPI: Key Performance Indicator; PICO: Population, Intervention, Comparator, Outcome; PMA: Pricing & Market Access; SOP: Standard Operating Procedure; PMO: Project Management Office; P&R: Pricing & Reimbursement.

We are ready for JCA — are you?

Reach out to the IQVIA EU HTA Solutions team to discuss your needs at: EUHTASolutions@iqvia.com



CONTACT US
EUHTASolutions@iqvia.com
iqvia.com/euhta